• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Development Officer Hall Ashley covered exercise/tax liability with 6,021 units of Ordinary Shares, decreasing direct ownership by 5% to 112,317 units (SEC Form 4)

    9/22/25 9:25:06 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GPCR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Hall Ashley

    (Last) (First) (Middle)
    C/O STRUCTURE THERAPEUTICS INC.
    601 GATEWAY BLVD., SUITE 900

    (Street)
    SOUTH SAN FRANCISCO CA 94080

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Structure Therapeutics Inc. [ GPCR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Development Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    09/18/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Ordinary Shares(1) 09/18/2025 F 6,021(2) D $7.7433 112,317 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.
    2. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.
    /s/ Jun Yoon, Attorney-in-Fact 09/22/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $GPCR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GPCR

    DatePrice TargetRatingAnalyst
    5/2/2025$60.00Buy
    Citigroup
    2/28/2025Outperform
    William Blair
    1/8/2025$50.00Buy
    Stifel
    12/4/2024$80.00Buy
    H.C. Wainwright
    9/23/2024$118.00Overweight
    Morgan Stanley
    5/21/2024$65.00Overweight
    JP Morgan
    4/9/2024$65.00Overweight
    Cantor Fitzgerald
    10/19/2023$90.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $GPCR
    SEC Filings

    View All

    Structure Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Structure Therapeutics Inc. (0001888886) (Filer)

    12/10/25 5:06:57 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Structure Therapeutics Inc.

    424B5 - Structure Therapeutics Inc. (0001888886) (Filer)

    12/10/25 5:04:01 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Structure Therapeutics Inc.

    424B5 - Structure Therapeutics Inc. (0001888886) (Filer)

    12/8/25 5:28:16 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GPCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

    SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the closing of its previously announced upsized underwritten public offering of 9,961,538 American depositary shares (ADSs), each representing three ordinary shares, which includes the full exercise of the underwriters' option to purchase up to 1,500,000 additional ADSs at a price to the public of $65.00 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at a price to the public of $64.9999 per pre-funded warrant. All of the secu

    12/11/25 4:01:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

    SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the pricing of its upsized underwritten public offering of 8,461,538 American depositary shares (ADSs), each representing three ordinary shares, at a price to the public of $65.00 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at a price to the public of $64.9999 per pre-funded warrant. All of the securities in the offering are being sold by Structure Therapeutics. The gross proceeds to Structure Therapeutics from the offeri

    12/9/25 11:15:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

    SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the commencement of a proposed underwritten public offering, subject to market and other conditions, to issue and sell $500 million of American depositary shares (ADSs), each representing three ordinary shares, or for certain investors that so choose, in lieu of ADSs, pre-funded warrants to purchase ordinary shares, represented by ADSs. All securities are being offered by Structure Therapeutics. In connection with the proposed offering,

    12/8/25 4:01:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GPCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by See Remark 1 Fmr Llc

    4 - Structure Therapeutics Inc. (0001888886) (Issuer)

    12/10/25 2:07:23 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF MEDICAL OFFICER Coll Crespo Blas covered exercise/tax liability with 8,106 units of Ordinary Shares, decreasing direct ownership by 4% to 216,807 units (SEC Form 4)

    4 - Structure Therapeutics Inc. (0001888886) (Issuer)

    9/22/25 9:25:04 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Hall Ashley covered exercise/tax liability with 6,021 units of Ordinary Shares, decreasing direct ownership by 5% to 112,317 units (SEC Form 4)

    4 - Structure Therapeutics Inc. (0001888886) (Issuer)

    9/22/25 9:25:06 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GPCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Structure Therapeutics with a new price target

    Citigroup initiated coverage of Structure Therapeutics with a rating of Buy and set a new price target of $60.00

    5/2/25 8:15:19 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Structure Therapeutics

    William Blair initiated coverage of Structure Therapeutics with a rating of Outperform

    2/28/25 7:24:16 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Structure Therapeutics with a new price target

    Stifel initiated coverage of Structure Therapeutics with a rating of Buy and set a new price target of $50.00

    1/8/25 7:51:31 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GPCR
    Leadership Updates

    Live Leadership Updates

    View All

    Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer

    SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive its next phase of development and operational success. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D. as part of a planned succession, effective September 18. Dr. Coll has served as Vice President of Clinical Development at Structure since 2022, leading the GSBR-1290 program, Structure's oral small molecule GLP-1 agonist that is planned to enter Phase

    9/17/24 4:05:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Structure Therapeutics Appoints Angus C. Russell to Board of Directors

    SAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the appointment of Angus C. Russell to its board of directors. Mr. Russell previously served as Chief Executive Officer of Shire plc and brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry. "Structure is at an important moment in its evolution as we prepare to advance our oral small molecule GLP-1 agonist, GSBR-1290, into late-stage clinical development for obesity," said Raymond Steve

    8/27/24 4:05:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

    Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290 Topline data from Phase 2a and Phase 1b multiple ascending dose study of GSBR-1290 expected in latter half of fourth quarter 2023 SAN FRANCISCO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the second quarter June 30, 2023, and highlighted recent corporate achievements. "We have continued our momentum and are on track to report topline data from our fully-enrolled Phase 2a study of GSBR-129

    8/10/23 4:05:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GPCR
    Financials

    Live finance-specific insights

    View All

    Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

    Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation  Placebo-adjusted mean weight loss up to 15.3% (35.5 lbs) observed with 240 mg dose in the exploratory ACCESS II study at 36 weeks No adverse event-related treatment discontinuations observed when starting at lower 2.5 mg dose in ACCESS Open Label Extension and Body Composition Study Data comprehensively support and inform advancement to Phase 3 clinical development program in mid-2026 Company to host conference call today at 8:30 a.m. Eastern Time SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutic

    12/8/25 8:00:00 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

    SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced plans to release topline data from its ACCESS clinical program of aleniglipron, the company's once-daily oral small molecule GLP-1 receptor agonist for the treatment of obesity, before the market opens on Monday, December 8, 2025. Members of management will host a conference call and webcast to discuss the data at 8:30 a.m. ET the same day. To access the live webcast, please visit the Investor Relations page of the company's website at

    12/7/25 6:20:23 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

    Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most advanced oral small molecule amylin-based drug candidate, with Phase 1 study initiation expected by year end 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced the selection of its lead oral small molecule amylin receptor agonist, ACCG-2671. Amy

    12/17/24 4:01:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GPCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Structure Therapeutics Inc.

    SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

    11/14/24 5:46:12 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Structure Therapeutics Inc.

    SC 13G - Structure Therapeutics Inc. (0001888886) (Subject)

    11/14/24 10:26:11 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Structure Therapeutics Inc.

    SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

    11/14/24 9:33:27 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care